Eosinophil Counts in Adults With Asthma Treated with Anti-IL-4Rα Rademikibart
CHEST · 2026-09 · 170 (3) · 689-700
DOI: 10.1016/j.chest.2026.04.019 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CHEST, 2026-09. Verfasst von Michael E Wechsler und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Jewish Health, Denver, CO. Hauptthemen laut MEDLINE: Eosinophils, Asthma, Anti-Asthmatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Eosinophil counts increased with IL-4Rα inhibition in phase 3 trials. Rademikibart, a next-generation IL-4Rα inhibitor, resulted in rapid lung function improvements, sustained across 24 weeks of treatment, in adults with uncontrolled moderate-to-severe asthma during the CBP-201-WW002 phase 2b trial. RESEARCH QUESTION: Is treatment-emergent hypereosinophilia a class effect of IL-4Rα inhibition, or does it differ with rademikibart? STUDY DESIGN AND METHODS: As in previous phase 3 trials of anti-IL-4Rα therapy, patients with eosinophil counts > 1,500 cells/μL at screening were excluded from this phase 2b trial of rademikibart. Blood eosinophil counts were analyzed in 322 patients randomized to rademikibart 150 or 300 mg every 2 weeks (after a 600-mg loading dose) vs placebo. The study included 24-week treatment and 8-week follow-up periods. RESULTS: In rademikibart 150-mg, 300-mg, and placebo groups, respectively, mean eosinophil counts (268, 320, and 299 cells/μL at baseline) changed by -8, -25, and 2 cells/μL at week 12 and by -30, -97, and -23 cells/μL at week 24. In a post hoc analysis of patients with ≥ 500 cells/μL at baseline, > 1,500 cells/μL were experienced by 10.0% of patients treated with rademikibart (n = 3) vs 18.8% of patients treated with placebo (n = 3). In patients with 1,500 cells/μL were experienced by 1.1% of patients treated with rademikibart (n = 2) vs 1.1% of patients treated with placebo (n = 1). One patient experienced > 3,000 cells/μL during off-treatment follow-up (rademikibart 150-mg group). Two patients (rademikibart 300-mg group) experienced nonserious grade 1 treatment-emergent adverse events of eosinophil count increased (n = 2) and eosinophil percentage increased (n = 1). No clear differences occurred in infection or cardiovascular treatment-emergent adverse events per treatment group. INTERPRETATION: Exploratory analyses suggest that rademikibart therapy may not result in hypereosinophilia; however, larger confirmatory analyses are required. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT04773678; URL: www. CLINICALTRIALS: gov.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Jewish Health, Denver, CO.
- Connect Biopharma LLC, San Diego, CA.
- Connect Biopharma LLC, San Diego, CA. Electronic address: rcollazo@connectpharm.com.
Zitieren
APA
Wechsler, M. E., Quart, B., & Collazo, R. (2026). Eosinophil Counts in Adults With Asthma Treated with Anti-IL-4Rα Rademikibart. CHEST, 170(3), 689-700. https://doi.org/10.1016/j.chest.2026.04.019
Vancouver
Wechsler ME, Quart B, Collazo R. Eosinophil Counts in Adults With Asthma Treated with Anti-IL-4Rα Rademikibart. CHEST. 2026;170(3):689-700. doi:10.1016/j.chest.2026.04.019
BibTeX
@article{Wechsler2026,
author = {Wechsler, Michael E and Quart, Barry and Collazo, Raúl},
title = {Eosinophil Counts in Adults With Asthma Treated with Anti-IL-4Rα Rademikibart},
journal = {CHEST},
year = {2026},
volume = {170},
number = {3},
pages = {689--700},
doi = {10.1016/j.chest.2026.04.019}
}
EUVIMED